“Rising burden of various diseases due to unhealthy lifestyle choices, increasing prevalence of sports injuries, growing usage of peripheral nerve stimulators & electronic pulse stimulators, and increase in the senior population affected by neurological diseases are factors driving market growth,”
South Korea, Seoul, Sept. 05, 2022 (GLOBE NEWSWIRE) -- According to Fact.MR, a market research and competitive intelligence provider, the global electrical stimulation devices market is expected to reach a valuation of US$ 11 billion by 2027, expanding at a high CAGR of 8% from 2022 to 2027.
Electrical stimulation devices are displaying potential as a rehabilitation technique in physiotherapy around the world, especially gaining ground over other established technologies. Electric impulses are used by electrical stimulation devices to electrically stimulate and contract muscles. The range of these devices is inspiring considerable interest among patients, including those requiring physiotherapy to manage chronic pain and athletes to meet specific training objectives. Market growth is mainly attributed to technological developments such as the creation of tools that can electrically stimulate the nervous system to restore vision and regain post-paralysis muscular motions.
Sales of electrical stimulation devices are expected to increase as more people use advanced stimulation techniques to activate injured muscles or manipulate underlying nerves to reduce pain. These portable, affordable devices help hasten the healing process and improve blood flow to the injured area. One of the major problems addressed by healthcare systems is chronic pain. Demand for electrical stimulation devices is primarily driven by the increasing prevalence of chronic pain and growing product usage for pain management as a result of their significant therapeutic benefits.
Get Sample PDF of This Research Report with Detailed Table of Content: https://www.factmr.com/connectus/sample?flag=S&rep_id=7666
Increasing prevalence of spinal injuries caused by accidents, violence, or falling is one of the main causes driving the market for electrical stimulation devices. This trend is expected to increase demand for spinal surgeries and drive market expansion at a rapid pace over the coming years.
Key Takeaways from Market Study
The global electrical stimulation devices market is currently valued at US$ 7.5 billion.
Market in Canada is anticipated to rise at a CAGR of 6.5% over the forecast period (2022-2027).
Sales of deep brain stimulation devices are expected to surge at a CAGR of 8.5% from 2022 to 2027.
Market in Germany is projected to expand at a CAGR of 6.7% through 2027.
Market players are focusing on getting speedy clearance for the marketing and distribution of their products. Key companies are focused on releasing advanced products to meet the significant unmet medical demands. Market participants are emphasizing their efforts and resources on R&D to meet varied patient requirements.
In 2021, Abbott announced NeuroSphere myPath, a digital health app intended to monitor and report pain reduction and overall wellness in patients undergoing spinal cord stimulation.
https://www.factmr.com/connectus/sample?flag=AE&rep_id=7666
Segmentation of Electrical Stimulation Devices Industry Research
Spinal Cord Stimulation (SCS) Devices
Deep Brain Stimulation (DBS) Devices
Vagus Nerve Stimulation (VNS) Devices
Sacral Nerve Stimulation (SNS) Devices
Neurological & Movement Disorder Management
Quick Buy – Electrical Stimulation Devices Market Research Report: https://www.factmr.com/checkout/7666
More Valuable Insights on Offer
Fact.MR, in its new offering, presents an unbiased analysis of the global electrical stimulation devices market, presenting historical demand data (2017-2021) and forecast statistics for the period of 2022-2027.
The study divulges essential insights on the market on the basis of device (spinal cord stimulation (SCS) devices, deep brain stimulation (DBS) devices, vagus nerve stimulation (VNS) devices, sacral nerve stimulation (SNS) devices, others), application (pain management, neurological & movement disorder management, musculoskeletal disorder management, metabolism & GIT management, others), and end user (hospitals, ambulatory surgical centers, others), across five major regions (North America, Europe, Asia Pacific, Latin America, and MEA).
Check out more related studies published by Fact.MR Research:
Optic Nerve Disorders Drugs Market - Optic nerve disorder, commonly known as optic neuropathy, is a medical condition indicating degeneration of the optic nerve. While mostly optic nerve disorders are hereditary, few of them are also acquired over the time. Some of probable etiologies (set of causes) leading to optic nerve disorders can include nutritional, ischemic, and toxic types.
Occipital Nerve Block Treatment Market - Occipital nerve block treatment is a therapeutic procedure which is used for the treatment of pain that occurs at the back of the head. The occipital nerve block treatment procedure is performed by the use of steroid injections or by giving local anesthetic to the base of the skull.
Spinal Bulbar Muscular Atrophy Treatment Market - Spinal and bulbar muscular atrophy is also called Kennedy disease. It is a disorder of the nerve cells that control muscle movement. These nerve cells are present in the brainstem. Spinal and bulbar muscular atrophy mainly occurs in males, and is characterized by atrophy that usually arises in adulthood.
Spinal Surgery Tables Market - There are various conditions which affects the spinal cord adversely which results into the back pain, adversely affecting the body movement, etc. The spinal conditions such as degenerative disk disease, fractures, scoliosis, spondylolisthesis, spine infection or tumor, etc. results in disturbing the normal functioning of the spinal cord.
Spinal Surgery Products Market - Demand for spinal implants and surgical devices has increased with the cost of products coming down all the time. As a result, the market for spinal surgery equipment is expanding steadily across the world.
Brain Tissue Oxygen Monitoring Systems Market - The brain tissue oxygen monitoring systems are employed for the continuous monitoring of oxygen partial pressure in the brain, thus providing early warning of hypoxic events, thereby allowing timely intervention to restore oxygen delivery. Brain tissue oxygen monitoring systems are used for patients suffering from traumatic brain injury and cerebral vascular events such as strokes & others.
Brain Base Knife Package Market - Brain base knife package is used for treatment of brain tumors. Brain tumor is an unwanted and abnormal growth of tissue in the brain which could either originate in the brain called the primary tumor or travel from any other body part to the brain called secondary or metastatic tumor.
Brain Implants Market - The global brain implants market is valued at US$ 6.6 billion in 2022 and is predicted to expand at a high-value CAGR of 11% to reach US$ 11.1 billion by the year 2027. Sales of deep brain stimulators are expected to increase at a similar CAGR of 11% from 2022 to 2027.
Preclinical Brain Imaging Market - Preclinical imaging is a technique used to monitor animals for research purposes such as in new drug development. Preclinical imaging includes many different imaging modalities, in which only few are suitable for imaging small animals, and others can be used in large animals. Preclinical imaging is used by researchers in visualizing changes in animal’s molecular, tissue and organ system.
Market research and consulting agency with a difference! That’s why 80% of Fortune 1,000 companies trust us for making their most critical decisions. While our experienced consultants employ the latest technologies to extract hard-to-find insights, we believe our USP is the trust clients have on our expertise. Spanning a wide range – from automotive & industry 4.0 to healthcare & retail, our coverage is expansive, but we ensure even the most niche categories are analyzed. Our sales offices in United States and Dublin, Ireland. Headquarter based in Dubai, UAE. Reach out to us with your goals, and we’ll be an able research partner. Contact: Mahendra Singh US Sales Office: 11140 Rockville Pike Suite 400 Rockville, MD 20852 Email: sales@factmr.com Tel: +1 (628) 251-158
Nursing homes and debt collectors are billing and suing long-term-care residents’ family members and friends, demanding payments for debts these individuals don’t legally owe, consumer attorneys and federal regulators are claiming. Under federal law, nursing homes participating in Medicare and Medicaid can’t make such provisions a condition of admission or continued stay in the facility.
Regeneron's Eylea eye-disorder drug faces competitive pressure on multiple fronts. New data could cement its dominance.
Immunocore Holdings plc (NASDAQ: IMCR) released initial Phase 1 data for the first off-the-shelf ImmTAC targeting PRAME, demonstrating that IMC-F106C is well tolerated and resulted in durable responses across multiple solid tumor types. Fifty-five patients have been treated across ten dose cohorts. IMC-F106C was well-tolerated, with treatment-related adverse events that were manageable and consistent with the mechanism of action. In the clinically active dose cohorts, durable partial responses (
When planning for the future, health care ranks as one of the highest concerns for both savers and retirees alike. Not only are health care costs rising by more than 5% every year, but rampant inflation and volatile market performances … Continue reading → The post New Bill May Allow Penalty-Free 401(k) Withdrawals for This Retirement Expense appeared first on SmartAsset Blog.
Shares of Shuttle Pharmaceuticals Holdings (NASDAQ: SHPH) climbed 160.4% this week, according to data from S&P Global Intelligence. The stock closed at $14.90 last Friday and then opened this Tuesday at $12.16. The stock began trading on Aug. 31 after its initial public offering (IPO).
These strategies can help you reduce your health care costs.
Jefferies upgrades the stock and other analysts raise their price targets on Regeneron following better-than-expected data on a new formulation of the company's signature eye medication.
ALBANY, N.Y. — New York declared a state of emergency on Friday to boost vaccinations against polio. Gov. Kathy Hochul issued an executive order expanding the state’s network of vaccine administrators to EMS workers, midwives and pharmacists as evidence mounts that the once rare virus is spreading in the state. Only one case of paralytic polio has been recorded in Rockland County so far, but ...
"The nasal vaccine is the best way to stop transmission or block it to the hilt,” says Dr. Eric Topol.
Mirati Therapeutics Inc (NASDAQ: MRTX) announced results from the KRYSTAL-1 Phase 1/2 study of adagrasib with or without cetuximab in patients with advanced colorectal cancer (CRC) harboring a KRASG12C mutation. The data will be presented at the European Society for Medical Oncology (ESMO) Congress 2022. In this analysis, 44 patients received adagrasib monotherapy, and 32 received the combination of adagrasib + cetuximab, with a follow-up of 20.1 months and 17.5 months, respectively. Related: Mi
The FDA's PCNSDAC recommends granting marketing approval to Amylyx's (AMLX) oral drug, which slows the progression of ALS.
The updated omicron-specific COVID-19 booster is important to get right away, a doctor says.
What does it mean to be under "medical supervision" like Queen Elizabeth II was? Buckingham Palace said the queen had medical supervision before her death.
The drugmaker's shares are skyrocketing in response to a positive advisory committee vote for its amyotrophic lateral sclerosis (ALS) drug candidate AMX0035. Specifically, a panel of experts assembled by the Food and Drug Administration (FDA) reportedly voted seven to two in favor of the available evidence supporting the drug's use as a treatment for ALS. ALS is a progressive neurodegenerative disorder that results in the loss of motor control.
Studies "support aflibercept 8 mg as a potential new standard-of-care," Regeneron Pharmaceuticals said. Regeneron stock leapt in huge volume.
Legal marijuana has boosted a violent black market, and today's highly potent forms are more addictive, especially among young people.
Relay Therapeutics Inc's (NASDAQ: RLAY) ReFocus trial for RLY-4008 was published on the European Society for Medical Oncology's (ESMO) website. The abstract has been selected for an oral presentation at the upcoming ESMO Congress 2022. Relay Therapeutics is evaluating RLY-4008, its bile duct cancer drug, for a narrow group of patients with FGFR2-altered cholangiocarcinoma. Related: Relay Therapeutics Highlights Interim Data From Bile Duct Cancer Trial. Potent efficacy was observed across all dos
Parkinson's disease (PD) may be an issue that stems from the health and function of your brain, according to the National Institute on Aging. However, a new study recently published by JAMA Network Open also reveals a connection between eating habits and mortality rates for those with PD.In a study titled "Association of Diet and Physical Activity With All-Cause Mortality Among Adults With Parkinson Disease," researchers took a look at 1,251 participants who were previously diagnosed with Parkin
Analysts say the drug, from Revance Therapeutics, poses a threat to the market-dominating antiwrinkle treatment because it promises to last longer.
CLAIM: A federal court order in the legal dispute over government documents held by former President Donald Trump shows President Joe Biden ordered the FBI search at Trump’s Florida home. THE FACTS: While Monday's court order from U.S. District Judge Aileen Cannon does include the phrase “as requested by the incumbent president” it’s not related to last month’s search at Mar-a-Lago. The phrase comes from a May letter from the National Archives denying Trump’s request to delay turning over documents to the FBI.